Research has unveiled a potential association between COVID-19 vaccines and Takotsubo cardiomyopathy, with two fatalities among 16 patients.
A Case Study In August, a case report was published in the journal Cureus detailing the experience of a 59-year-old woman who developed Takotsubo cardiomyopathy after receiving a booster dose of the COVID-19 vaccine.
The researchers stated that the pathophysiology of COVID-19 vaccine-induced Takotsubo cardiomyopathy is not yet clear, but that "Several theories have been proposed." The immune response triggered by COVID-19 vaccines may, for some individuals, "Result in an exaggerated inflammatory cascade, leading to endothelial dysfunction, microvascular dysfunction, and myocardial injury." Vaccination may also stimulate the release of pro-inflammatory factors such as interleukin-6.
The stress response induced by COVID-19 vaccination could potentially "Dysregulate the autonomic nervous system, contributing to the development of cardiac dysfunction." Takotsubo Cardiomyopathy Poses a Life-Threatening Risk The association between COVID-19 vaccines and Takotsubo cardiomyopathy is not widely known, with only a few reported cases.
Seven patients developed Takotsubo cardiomyopathy after the first dose and seven after the second dose.
The researchers noted that 87.5 percent of patients recovered and were discharged, indicating that Takotsubo cardiomyopathy occurring after vaccination is mostly "Transient and reversible." However, the death of 2 of the patients highlights the "Potentially life-threatening nature of this vaccine-related adverse event."
The paper's authors urge clinicians to consider the possibility of Takotsubo cardiomyopathy, especially among recipients of mRNA vaccines when presented with patients experiencing chest pain or dyspnea symptoms after vaccination.
No comments:
Post a Comment